ASSET PURCHASE AGREEMENT
This ASSET PURCHASE AGREEMENT (the "Agreement") is made as of June 28,
1999, between OPUS DIAGNOSTICS, INC., a Delaware corporation ("Buyer"), and OXIS
HEALTH PRODUCTS, INC. a Delaware corporation ("Seller" or "OXIS"). Seller
desires to sell, and Buyer desires to buy, Seller's TDM Business as described
herein. OXIS International, Inc., a Delaware corporation, and the parent
corporation of OXIS ("OXIS International") is also executing this agreement for
the sole purpose of agreeing to the terms of Article 10 hereof.
NOW, THEREFORE, Buyer and Seller hereby agree as follows:
ARTICLE 1
TRANSFER OF ASSETS
1.1 AGREEMENT TO SELL. Upon the terms and subject to all of the conditions
contained herein, Seller hereby agrees to sell, assign, transfer and deliver to
Buyer on the Closing Date (as defined in Article 3), and Buyer hereby agrees to
purchase from Seller on the Closing Date, the Assets (as defined in Section 1.2)
comprising Seller's therapeutic drug monitoring assay business as described in
Schedule 1.1 hereto (the "TDM Business").
1.2 DESCRIPTION OF ASSETS. For purposes of this Agreement, the term
"Assets" shall include, without limitation, all of the following assets:
1.2.1 All rights, title and interest of Seller in and to the contracts
and agreements listed on Schedule 4.5 attached hereto (collectively, the
"Contracts") relating to the operation of the TDM Business;
1.2.2 All of Seller's finished goods inventory (but not raw materials
or work-in-process) relating solely to the TDM Business as of the Closing Date
(the "Inventory"). Schedule 4.4 sets forth a list of the Inventory as of the
date hereof;
1.2.3 All patents, patent applications, software, product designs,
trademarks, trademark applications, service marks, service ▇▇▇▇ applications,
trade and other marks and names (either registered, common law or registration
applied for), copyrights, copyright applications, mask works, inventions, trade
secrets, proprietary information, know-how, processes, manufacturing or
marketing procedures, recipes, formulae, drawings, schematics and patterns, and
all documentation and other media ("Intellectual Property") relating to the TDM
Business owned by Seller or with respect to which Seller has a license, interest
or other right to use (all such Intellectual Property, collectively, the "Seller
Intellectual Property"). The Seller Intellectual Property includes, without
limitation, the Intellectual Property listed on Schedule 4.8. Without limitation
of the foregoing, the Assets shall be deemed to further include all drawings,
documentation, schematics, labeling, manuals or other materials, whether in
written or magnetic form that describe, disclose or otherwise set forth any of
the Seller Intellectual Property, and all correspondence relating thereto (which
Seller possesses); and
1.2.4 All goodwill, marketing materials, research materials, quality
control documents used in the manufacture of the Products, licenses, permits,
FDA files and grant applications specifically relating to the TDM Business.
1.3 EXCLUDED ASSETS. The following assets of Seller are not included in the
definition of Assets for purposes of Section 1.2 and will not be purchased by
Buyer (the "Excluded Assets"): (a) all accounts receivable, and (b) all
equipment and other tangible assets (including raw materials and
work-in-process) related to the manufacturing and production of the assays and
other products comprising the TDM Business.
1.4 LIABILITIES. Any and all liabilities of or related to the TDM Business
incurred prior to the Closing shall remain liabilities of the Seller, which
shall be paid or otherwise satisfied by the Seller when such liabilities become
due. The Buyer is not assuming or otherwise becoming liable for liabilities of
or related to the TDM Business incurred prior to the Closing. Notwithstanding
the foregoing, Buyer shall be assuming the obligations under the Contracts with
respect to future performance thereunder. ARTICLE 2 PURCHASE PRICE
2.1 PURCHASE PRICE. As full consideration for the sale, assignment,
transfer and delivery of the Assets by Seller to Buyer, upon the terms and
subject to all of the conditions contained herein (and the performance by each
of the parties hereto of their respective obligations hereunder), the purchase
price will consist of the following (collectively, the "Purchase Price"):
2.1.1 Cash in the amount of Five Hundred Thousand Dollars ($500,000.00)
to be paid in immediately available funds at the Closing (the "Cash Purchase
Price");
2.1.2 A secured promissory note in the principal amount of Five Hundred
Sixty-Five Thousand Dollars ($565,000.00), (subject to (i) reduction in an
amount equal to the difference between $135,000 minus the value of the Inventory
as of Closing, in the event the value of the Inventory as of Closing is less
than $135,000 or (ii) increase in an amount equal to the difference between the
value of the Inventory as of Closing minus $135,000, in the event the value of
the Inventory as of Closing is greater than $135,000), due and payable on
November 30, 1999, subject to prepayment without penalty, executed by Buyer to
the order of Seller, substantially in the form of Exhibit A attached hereto (the
"1999 Note");
2.1.3 A warrant (the "Warrant") evidencing Seller's right to acquire up
to a ten percent (10%) equity interest in Buyer pursuant to the terms and
conditions set forth in the Warrant, a copy of which is attached hereto as
Exhibit B.
2.2 SECURITY. Repayment of the 1999 Note will be secured by a security
interest (the "Security Interest") granted by Buyer in favor of Seller in the
Assets which Security Interest will be a perfected, first priority security
interest in favor of Seller. Buyer represents and warrants that the Security
Interest when properly filed will be a first perfected security interest prior
to any and all other claims, liens, encumbrances or security interests of any
kind with respect to the Assets.
ARTICLE 3
CLOSING
3.1 CLOSING. The transactions contemplated by this Agreement shall close
(the "Closing") on June 28, 1999, at 5:01 p.m., California time (the "Closing
Date"). The Closing shall occur upon the satisfaction of all the conditions set
forth in this Article 3 and Article 8 and shall be held in the offices of
▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, ▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇.
3.2 DOCUMENTS DELIVERED BY SELLER AT CLOSING. Seller will cause good and
marketable title to all of the Assets to be transferred to Buyer at the Closing,
free and clear of all liens, encumbrances, charges, security interests, claims,
restrictions or rights of others (collectively, "Liens"). Without limiting the
foregoing, Seller will take or cause to be taken any and all actions necessary
or otherwise reasonably required by Buyer to ensure that at the Closing Buyer
acquires possession of and good and marketable title to all of the Assets, free
and clear of all Liens. At the Closing, Seller will deliver to Buyer the
following documents (collectively, the "Seller Closing Documents"), executed by
Seller, where applicable, and in form satisfactory to Buyer:
(a) a ▇▇▇▇ of Sale in substantially the form of Exhibit C attached
hereto;
(b) an Assignment of Intangible Property in substantially the form of
Exhibit D attached --------- hereto;
(c) the Services Agreement in substantially the form of Exhibit E
attached hereto;
(d) an itemization of the Inventory as of Closing (the value of such
Inventory for purposes of Section 2.1.2 hereof shall be deemed to be the book
value of such Inventory as set forth in Seller's books and records, as
determined under generally accepted accounting principles applied consistently
with Seller's past practices);
(e) a schedule of Seller's accounts receivable relating to the TDM
Business, as of the Closing Date;
(f) resolutions of the Board of Directors of Seller authorizing the
consummation of the transactions contemplated hereby, certified by the Secretary
of Seller;
(g) all third-party consents (including, without limitation, from
parties to the Contracts) necessary for the consummation of the transactions
contemplated hereby;
(h) an opinion from ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ LLP, counsel to the Seller
dated the Closing Date in a form reasonably acceptable to Buyer;
(i) a certificate from the Seller's President in a form reasonably
acceptable to Buyer; and
(j) any other documents reasonably required by Buyer to transfer the
Assets in accordance with the terms of this Agreement.
3.3 DOCUMENTS DELIVERED BY BUYER AT CLOSING. At the Closing, Buyer will
deliver to Seller the following executed documents or consideration ("Buyer
Closing Documents"):
(a) the Cash Purchase Price;
(b) the 1999 Note;
(c) the Warrant;
(d) resolutions of the Board of Directors of Buyer authorizing the
consummation of the transactions contemplated hereby, certified by the Secretary
of Buyer ;
(e) UCC-1 Financing Statement to be filed with the New Jersey and
Oregon Secretary of State and any other documents necessary for perfecting the
Security Interest;
(f) an Assignment of Intangible Property in substantially the form of
Exhibit D attached --------- hereto;
(g) the Services Agreement in substantially the form of Exhibit E
attached hereto;
(h) an opinion from ▇▇▇▇▇▇ ▇▇▇▇ & Priest L.L.P., counsel to the Buyer
dated the Closing Date in a form reasonably acceptable to Seller;
(i) a certificate from the Buyer's President in a form reasonably
acceptable to Seller; and
(j) any other documents reasonably required by Seller to transfer the
Assets in accordance with the terms of this Agreement.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SELLER
Seller hereby represents and warrants to Buyer that the following facts and
circumstances are true and correct as of the date of this Agreement, except as
set forth on the schedule of exceptions attached hereto as Schedule 4 (the
"Seller Disclosure Schedule"):
4.1 ORGANIZATION. Seller: (a) is a corporation duly organized, validly
existing and in good corporate standing under the laws of the State of Delaware
and duly qualified as a foreign corporation in the State of Oregon; and (b) has
all necessary corporate power and authority to own and lease its properties, to
carry on its business as now being conducted and to enter into and perform this
Agreement and all of the other documents and agreements contemplated hereby.
4.2 AUTHORITY AND CONSENTS. The execution and performance of this Agreement
and the other documents to be executed by Seller pursuant to the terms hereof
will not result in a violation of Seller's Certificate of Incorporation or
Bylaws. Seller has full power and authority (corporate and otherwise) to enter
into this Agreement and the other documents to be executed by Seller pursuant to
the terms hereof and to carry out the transactions contemplated by this
Agreement and such other documents. This Agreement and the other documents to be
executed by Seller pursuant to the terms hereof and their execution and delivery
to Buyer have been duly authorized by the Board of Directors of Seller and no
further corporate action prior to the Closing is necessary on the part of Seller
or its shareholders to make this Agreement and the other documents to be
executed by Seller pursuant to the terms hereof and the transactions
contemplated by the Agreement and such other documents valid and binding upon
Seller. This Agreement and the other documents to be executed by Seller pursuant
to the terms hereof do and will constitute a legal, valid and binding obligation
of Seller, enforceable against Seller in accordance with their respective terms,
subject as to enforcement only: (a) to bankruptcy, insolvency, reorganization,
arrangement, moratorium and other similar laws of general applicability relating
to or affecting creditors' rights generally; and (b) to general principles of
equity. Unless listed on Schedule 4, no consent of any person not a party to
this Agreement and no consent of any governmental authority is required to be
obtained on the part of the Seller to permit the consummation of the
transactions contemplated by this Agreement.
4.3 TITLE TO ASSETS. Seller has good and marketable title to all of the
Assets and all of the Assets are free and clear of all Liens and upon transfer
of the Assets to Buyer, pursuant to this Agreement, the Buyer will have good and
marketable title to all of the Assets free and clear of all Liens except to the
extent provided herein or except that may arise due to Buyer's activities.
4.4 INVENTORY. Schedule 4.4 sets forth a true, correct and complete list of
the Inventory of Seller which is being sold to Buyer hereunder including an
itemization of the value thereof. All of such Inventory is in good and
merchantable condition and salable or useable in the ordinary course of the TDM
Business.
4.5 CONTRACTS. Schedule 4.5 constitutes a true, correct and complete list
of all Contracts. The Contracts comprise all contracts and agreements (written
or oral) relating to the TDM Business to which the Seller is a party or
otherwise bound. Each Contract is valid and enforceable in accordance with its
respective terms, Seller is not in default in the performance of any of its
obligations thereunder, no event of default has occurred which (whether with or
without notice, lapse of time, or both, or the happening or the occurrence of
any other event) would constitute such a default thereunder and, to Seller's
knowledge, all other parties thereto are not in default thereunder and have no
counterclaims, offsets and defenses with respect thereto and the Contracts are
assignable to Buyer under the terms thereof without the prior consent of the
other parties thereto (except as otherwise indicated on Schedule 4.5). Also set
forth on Schedule 4.5 is a list of all suppliers from which Seller has made
significant purchases of TDM raw materials since January 1, 1997. The Seller
shall make available (upon reasonable notice) to the Buyer at Seller's premises
(during business hours) copies of all correspondence received since January 1,
1998 from distributors of the products of the TDM Business (which Seller
possesses).
4.6 AGREEMENT WILL NOT CAUSE BREACH OR VIOLATION. Neither the execution nor
delivery of this Agreement or the other documents contemplated hereby by the
Seller, nor performance by Seller of the terms and provisions of this Agreement
or such other documents will (a) conflict with or result in a breach of or
default under any of the terms, conditions or provisions of any judgment, order,
injunction, decree, regulation or ruling of any court or governmental authority
to which Seller is subject or of any Contract or any other agreement, contract,
or commitment to which Seller is a party or by which it is bound, or (b) give
any "Person" (which term includes any individual, partnership, joint venture,
corporation, trust, unincorporated organization, any other entity and any
government or any department or agency thereof, whether acting in an individual,
fiduciary, or other capacity) the right to terminate or modify any Contract, or
accelerate any obligation or indebtedness of Seller thereunder.
4.7 FINANCIAL STATEMENTS. Seller has delivered to Buyer a statement of
revenues and expenses of the TDM Business for the years ended December 31, 1996,
1997 and 1998 and the fiscal quarters ended March 31, 1998 and 1999 (the
"Statement of Revenues and Expenses"). The Statement of Revenues and Expenses
was prepared from the accounts of the Seller and OXIS International, Inc., the
owner of the TDM Business prior to April 1, 1998, which accounts have been
prepared and maintained in accordance with generally accepted accounting
principles applied consistently during the period. Costs and expenses reported
in the Statement of Revenues and Expenses do not include amortization of
purchase price adjustments from business combinations. Cost and expenses include
all other costs directly attributable to the TDM Business and a reasonable
allocation of other costs incurred in carrying out the TDM Business. Seller is
not insolvent, bankrupt or subject to any insolvency procedure. Seller will
assist Buyer with questions or issues relating to the Statement of Revenues and
Expenses which arise after the Closing in connection with the preparation of
Buyer's financial statements, including providing access to Seller's independent
accountants, upon reasonable notice given and at the cost of Buyer.
4.8 INTELLECTUAL PROPERTY.
4.8.1 Seller owns and has good and marketable title to each item of
Seller Intellectual Property listed on Schedule 4.8, free and clear of any
Liens. No Seller Intellectual Property or product and/or technology of Seller is
subject to any outstanding decree, order, judgment, stipulation, license or
agreement restricting in any material manner the use or licensing thereof by
Seller.
4.8.2 The operation of Seller's TDM Business as it currently is
conducted, including its design, development, manufacture, use and sale of its
products and/or technology, and provision of services, does not, to the
knowledge of Seller, infringe the Intellectual Property of any other Person.
Seller has not received notice from any Person that the operation of Seller's
TDM Business, including its design, development, manufacture and sale of its
products and/or technology (including with respect to products and/or technology
currently under development) and provision of services, infringes the
Intellectual Property of any Person.
4.8.3 To the knowledge of Seller, no Person is infringing or
misappropriating any of the Seller Intellectual Property.
4.8.4 Seller has the unrestricted right to transfer and assign the
Seller Intellectual Property to Buyer.
4.8.5 To the knowledge of Seller, the Seller Intellectual Property
includes all Intellectual Property necessary to operate the TDM Business
(including the manufacture, marketing, commercialization (to the extent
necessary) and selling of the products comprising the TDM Business) to the same
extent and in the same manner as currently operated by Seller.
4.9 LITIGATION. To the best of Seller's knowledge, the Assets are not
the subject of any litigation, proceedings or controversies that are pending,
threatened or anticipated by or against Seller before any court, government
agency or any other administrative body.
4.10 ACCOUNTS RECEIVABLE. Seller's accounts receivable relating to the TDM
Business arose from valid sales in the normal course of business and are
collectible in the normal course of business at the aggregate recorded amount
thereof, less a reserve for doubtful accounts as shown in the Seller's general
ledger, and are not subject to any right of set-off by any customer of Seller.
Schedule 4.10 sets forth a complete and correct list of the top ten customers of
Seller's TDM Business for the year ended December 31, 1998 and the three months
ended March 31, 1999 showing the amount of revenues by product for each such
customer. No customer listed on Schedule 4.10 has informed Seller that it plans
to reduce or discontinue the amount of purchases of products it purchases from
Seller, although Seller makes no representation or warranty with respect to the
amount of products that such customers will purchase in the future.
4.11 COMPLIANCE WITH LAWS. All business and operations of the TDM Business
has been and is being conducted materially in accordance with all applicable
laws, rules and regulations of all Federal, state, local and governmental
authorities. Schedule 4.11 sets forth a complete and correct list of all
permits, licenses and other authorizations, including all clearances from the US
Food & Drug Administration and similar agencies in states or foreign
jurisdictions (collectively, the "Authorizations") obtained by or on behalf of
Seller in connection with the TDM Business. Seller holds all Authorizations
required by governmental authorities as may be necessary for the conduct of the
TDM Business, except where the failure to obtain any such permits, licenses or
other authorizations would not have a material adverse effect on the TDM
Business. To Seller's knowledge, Seller is not a party to any governmental
proceeding pending or threatened which might result in a suspension, limitation
or revocation of any Permit.
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF BUYER
Buyer hereby represents and warrants to Seller that the following facts and
circumstances are true and correct:
5.1 AUTHORIZATION; ETC. Buyer: (a) is a corporation duly organized, validly
existing and in good corporate standing under the laws of the State of Delaware;
and (b) has all necessary corporate power to own and lease its properties, to
carry on its business as now being conducted and to enter into and perform this
Agreement and all of the other documents and agreements contemplated hereby.
Buyer has full power and authority (corporate and otherwise) to enter into this
Agreement and the other documents to be executed by Buyer pursuant to the terms
hereof and to carry out the transactions contemplated hereby and thereby. Buyer
has taken all required action by law to authorize the execution and delivery of
this Agreement and the other documents contemplated hereby and the transactions
contemplated hereby and thereby, and this Agreement and the other documents
contemplated hereby is a valid and binding obligation of Buyer, enforceable
against it in accordance with their respective terms, subject as to enforcement
only: (i) to bankruptcy, insolvency, reorganization, arrangement, moratorium and
other similar laws of general applicability relating to or affecting creditors'
rights generally; and (ii) to general principles of equity.
5.2 NO VIOLATION. Neither the execution and delivery of this Agreement or
the other documents contemplated hereby by Buyer, nor the performance by Buyer
of the terms and provisions of this Agreement or such other documents will (a)
violate any provisions of the Certificate of Incorporation of Buyer, or (b)
violate, or be in conflict with, or constitute a default under, breach of, or
cause the acceleration of the maturity of any debt or obligation pursuant to,
any agreement or commitment to which Buyer is a party or by which Buyer is
bound, or (c) violate any statute or law or any judgment, decree, order,
regulation, or rule of any court or governmental authority.
5.3 VALID ISSUANCE. The Warrant is a valid and binding obligation of Buyer
enforceable against it in accordance with its terms subject, as to enforcement
only, to: (a) bankruptcy, insolvency, reorganization, arrangement, moratorium
and other similar laws of general applicability relating to or affecting
creditors' rights generally; and (b) general principles of equity. The common
stock of Buyer to be issued upon exercise of the Warrant has been reserved for
issuance and, upon due exercise of the Warrant, will be duly authorized, validly
issued, fully paid and nonassessable.
5.4 CONSENTS AND APPROVALS OF GOVERNMENT AUTHORITIES. No consent, approval
or authorization of, or declaration, filing or registration with, any
governmental or regulatory authority is required in connection with the
execution, delivery and performance of this Agreement or the other documents
contemplated hereby by Buyer and the consummation of the transactions
contemplated hereby or thereby.
5.5 CAPITALIZATION OF BUYER. Buyer has authorized 1,000,000 shares of
Common Stock, $0.01 par value, of which 20,000 shares are issued and
outstanding, and except for the Warrant, Buyer has no authorized or outstanding
options or securities convertible into or exercisable for shares of its Common
Stock.
5.6 INFORMATION. Buyer has concluded its due diligence review of the TDM
Business and acknowledges that it has had ample opportunity to visit with and
ask questions of Seller's management regarding the TDM Business and any
information Buyer has received related thereto. Notwithstanding such due
diligence review, Buyer is relying only upon the representations and warranties
of Seller herein in making its decision to purchase the TDM Business. The
foregoing due diligence review shall not limit, qualify or modify the
representations and warranties of Seller or the indemnities by Seller under this
Agreement, irrespective of the knowledge and information received by Buyer.
ARTICLE 6
COVENANTS
6.1 CONSENTS. On or prior to the Closing Date, Seller shall (a) notify all
persons required to be notified pursuant to applicable law or any of the
Contracts of the transactions contemplated hereunder, in the form and manner
required thereunder, except as set forth on Schedule 4.5, and (b) obtain the
consent of all persons whose consent is required pursuant to applicable law or
any of the Contracts in connection with the consummation of the transactions
contemplated hereby, in the form and manner required thereunder.
6.2 NOTIFICATION OF CERTAIN MATTERS. On or prior to the Closing Date,
Seller shall give prompt notice to Buyer of the occurrence or non-occurrence of
any event which would likely cause any representation or warranty made by Seller
herein to be untrue or inaccurate or any covenant, condition or agreement
contained herein not to be complied with or satisfied (provided, however, that
any such disclosure shall not in any way be deemed to (a) amend, modify or in
any way affect the representations, warranties and covenants made by such party
in or pursuant to this Agreement, or (b) alter or waive any rights of Buyer with
respect to the breach thereof).
6.3 CONTINUING OPERATION OF BUSINESS. Seller agrees to manufacture and
produce all requirements of Buyer with regard to the TDM Business, solely for
the benefit of Buyer in accordance with the Services Agreement substantially in
the form of Exhibit E attached hereto.
6.4 RIGHTS OF FIRST REFUSAL. Seller will provide Buyer a right of first
refusal for a period of one year from the Closing Date to purchase Seller's
Automated Fluorescence Technology in the event Seller determines to sell such
technology and receives a bona fide offer, or Seller makes a sale proposal to a
third party, related thereto. In such event, Seller shall notify Buyer in
writing of the terms and conditions of such offer and within fifteen (15)
business days of the receipt of such Notice, Buyer shall inform Seller in
writing whether it agrees to purchase the Automated Fluorescence Technology on
the same terms and conditions set forth in such Notice. If Buyer fails to agree
to purchase such technology within such fifteen (15) business day period, Seller
shall be free to sell such technology pursuant to the terms and conditions set
forth in the bona fide offer received. In the event the third party does not
purchase such technology or there are any changes in the terms and conditions of
such sale, this right of first refusal shall be reinstated, but in all events
expires one year from the Closing Date.
ARTICLE 7
COVENANTS
7.1 EXISTING CUSTOMERS. Until the 1999 Note is paid in full, Buyer will use
commercially reasonable efforts to continue to meet the needs of existing TDM
Business customers of Seller as of the Closing Date with regard to product
development, quality and support in accordance with good industry practices
subject to Seller fulfilling its obligations under the Services Agreement.
7.2 SELLER'S DEVELOPMENT RESOURCES. During the term of the Services
Agreement, Buyer will, whenever possible and provided that Seller is reasonably
competitive, utilize Seller's development resources for all of its development
of therapeutic drug monitoring assays using fluorescent polarization for use on
the ▇▇▇▇▇▇ Laboratories TDX and other technologies in which Seller has proven
skills and capabilities, provided, however, that Buyer has the right to seek
competitive bids from other providers for such assignments.
7.3 COOPERATION IN COLLECTION OF RECEIVABLES. Buyer will reasonably
cooperate and assist Seller with the collection of Seller's accounts receivable
relating to the TDM Business on the Closing Date as set forth in the schedule
referred to in Section 3.2(e) and Seller will instruct customers to make
payments to Buyer following the Closing. Buyer agrees to remit all receipts of
Seller's accounts receivable within three business days of receipt. Seller will
provide Buyer with a schedule for such accounts receivable at the Closing. Until
all of Seller's accounts receivable are paid in full excluding receivables
subject to a bona fide dispute documented in writing as of the Closing Date,
Buyer will follow Seller's existing credit policies and Seller (in connection
with its responsibilities under the Services Agreement) shall have the right to
refuse shipment of any products to any customer which has not paid an accounts
receivable on a timely basis consistent with the credit terms established by
seller relating to such accounts receivable. However, once a customer's balance
owed to Seller has been reduced to ten percent (10%) or less of that customers'
balance as of the Closing, Buyer may require Seller to ship products to that
customer regardless of any past due amount. Buyer shall have the option to
purchase any accounts receivable (at 100% of the stated amount) in order to
allow for the shipment of products to customers who have not paid accounts
receivable owed to Seller.
7.4 CHANGE OF DISTRIBUTORS. Prior to payment in full of the 1999 Note,
Buyer will not terminate any agreements with distributors that have been
assigned by Seller to Buyer without Seller's prior written approval, provided
that such approval shall not be unreasonably withheld. If Seller fails to notify
Buyer that it does not approve of the termination within seven business days of
receiving notice from Buyer that Buyer intends to terminate, Seller's approval
shall be deemed given.
7.5 PRICE INCREASES. Prior to payment in full of the 1999 Note, Buyer will
not increase prices to any former customer of Seller by more than ten percent
(10%) in the aggregate without Sellers' prior written approval, provided that
such approval shall not be unreasonably withheld.
7.6 CONTINUING OPERATION OF BUSINESS. Buyer will sublicense to Seller any
and all rights necessary to enable Seller to fulfill its obligations under the
Services Agreement.
ARTICLE 8
CONDITIONS TO CLOSING
8.1 CONDITIONS TO BUYER'S OBLIGATIONS AT THE CLOSING. Buyer's obligations
to consummate the transactions contemplated by this Agreement shall be subject
to the full satisfaction of the following conditions, each of which conditions
may be waived in writing by Buyer:
(a) Instruments. Seller shall have delivered all of the Seller Closing
Documents at the Closing.
(b) Representations and Warranties True; Performance of Covenants. The
representations and warranties of Seller contained in this Agreement shall be
true in all material respects at the Closing as though made at such time. Seller
shall have performed all obligations and complied with all covenants and
conditions required by this Agreement to be performed or complied with by it on
or prior to the Closing Date.
(c) Services Agreement. Buyer and Seller shall have entered into the
Services Agreement, in substantially the form of Exhibit E attached hereto.
(d) Consents. All consents or approvals required for the consummation
of the transactions contemplated hereby, including any required consents of the
parties to any Contract, shall have been obtained.
8.2 CONDITIONS TO SELLER'S OBLIGATIONS AT THE CLOSING. Seller's obligations
to consummate the transactions contemplated by this Agreement shall be subject
to the full satisfaction of the following conditions, each of which conditions
may be waived in writing by Seller:
(a) Instruments. Buyers shall have delivered all of the Buyer Closing
Documents at the Closing.
(b) Representations and Warranties True; Performance of Covenants. The
representations and warranties of Buyer contained in this Agreement shall be
true in all material respects at the Closing as though made at such time. Buyer
shall have performed all obligations and complied with all covenants and
conditions required by this Agreement to be performed or complied with by it at
or prior to the Closing Date.
(c) Consents. All material consents or approvals required for the
consummation of the transactions contemplated hereby shall have been obtained
(d) Services Agreement. Buyer and Seller shall have entered into the
Services Agreement, in substantially the form of Exhibit E attached hereto.
ARTICLE 9
SURVIVAL OF REPRESENTATIONS AND WARRANTIES
9.1 SURVIVAL. The representations and warranties of Seller and Buyer
contained in this Agreement or in any document, certificate or schedule or
instrument contemplated hereby or delivered pursuant hereto, shall survive the
Closing Date for a period of eighteen (18) months after the Closing Date.
9.2 INDEMNIFICATION BY SELLER. Seller agrees to indemnify Buyer and each of
its affiliates and officers, directors, employees and agents against, and agrees
to hold each of them harmless from, any and all losses, damages or expenses,
including reasonable attorney's fees, suffered or incurred by them arising out
of or relating to any of the following:
(a) any breach of any representation or warranty made by Seller in this
Agreement;
(b) any breach of or failure by Seller to perform any covenant or
obligation of Seller set out or contemplated in this Agreement or in any
schedule hereto;
(c) any products or other activities of the TDM Business produced or
services performed by Seller prior to the Closing Date;
(d) any liabilities of the TDM Business incurred by Seller prior to the
Closing Date; and
(e) any claims by or liabilities with respect to any employee of Seller
with respect to his or her employment or termination of employment on or prior
to the Closing Date by Seller.
9.3 INDEMNIFICATION BY BUYER. Buyer agrees to indemnify Seller and each of
its affiliates and officers, directors, employees and agents against, and agrees
to hold each of them harmless from, any and all losses, damages or expenses,
including reasonable attorney's fees, suffered or incurred by them arising out
of or relating to any of the following;
(a) any breach of any representation or warranty made by Buyer in this
Agreement;
(b) any breach of or failure by Buyer to perform any covenant or
obligation of Buyer set out or contemplated in this Agreement;
(c) any products produced or services performed by Buyer on or after
the Closing Date relating to the TDM Business (excluding claims arising from
services performed by Seller under the Services Agreement);
(d) any liabilities of the TDM Business incurred by Buyer on or after
the Closing date; and
(e) any claims by or liabilities with respect to any employee of Buyer
with respect to his or her employment by the Buyer.
9.4 NOTICE OF CLAIMS. PROCEDURE FOR INDEMNIFICATION. Upon becoming aware of
a claim for indemnification hereunder, the indemnified party shall promptly give
notice of such claim to the indemnifying party, providing reasonable details of
how the claim has arisen and an estimate of the amount the indemnified party
reasonably anticipates that it will be entitled to on account of indemnification
by the indemnifying party. If the indemnifying party does not object to such
indemnification claim within fifteen (15) calendar days of receiving notice
thereof, the indemnified party shall be entitled to recover promptly the amount
of such claim but such recovery shall not limit the amount of any additional
indemnification to which the indemnified party may be entitled to pursuant to
Section 9.2 or 9.3 hereof. If, however, the indemnifying party advises the
indemnified party that it disagrees with the indemnified party's claim, the
parties shall, for a period of thirty (30) calendar days after the indemnifying
party advised the indemnified party of such disagreement, attempt to resolve the
difference and, failing to do so in such time, either party may unilaterally
submit the matter to dispute resolution pursuant to Section 12.5 hereof.
9.5 THIRD PARTY'S CLAIMS. Claims asserted by a third party, which Buyer or
Seller has determined may give rise to claim indemnification pursuant to Section
9.2 or 9.3 hereof, shall be subject to the following additional procedure and
conditions:
(a) The indemnified party shall give notice to the indemnifying party
of the occurrence of any event or the institution of any claim, action,
investigation, suit or proceeding asserted by a third party which the
indemnified party has determined has given, or may give, rise to claim
indemnification under Section 9.2 or 9.3 hereof. Such notice shall be given
promptly after the indemnified party becomes aware of the event or claim so as
to allow the indemnifying party to present to the indemnified party any argument
that the indemnifying party may wish to raise in connection with the defense of
such claim, provided, however, that where a defense or answer to the asserted
claim must be submitted within a specified period, failing which shall preclude
the indemnified party from asserting such defense or giving such answer, notice
of the claim shall be given to the indemnifying party no later than at the
expiration of one-half (1/2) of such specified period. Any failure by an
indemnified party to give notice of a third party claim shall not affect its
right to indemnification hereunder except to the extent the indemnifying party
can show it was adversely affected by the failure to receive timely notification
and such limitation shall be only to the extent it was so adversely affected.
(b) The indemnifying party shall, upon receipt of the notice referred
to in Section 9.5(a) above, be entitled to conduct the defense, appeal or
settlement of such claim, with counsel elected by it, by giving notice to the
indemnified party of its election to do so within ten (10) calendar days
following receipt by it of the notice of the claim, and the indemnified party
shall thereupon provide the indemnifying party access to the documents relevant
to such defense, appeal or settlement. In the event that the indemnifying party
elects not to conduct the defense, appeal or settlement of such claim, the
indemnified party shall have the right to conduct the defense thereof or reach a
settlement in connection therewith on behalf of and on the account and risk of
the indemnifying party.
9.6 LIMITATIONS. Notwithstanding any provision of this Agreement to the
contrary, an indemnifying party shall not be liable for indemnification to the
other party until the aggregate of all losses, liabilities and damages
(including expenses) incurred by such other party exceed US $25,000, and then
the obligation of the indemnifying party shall be for all such losses of the
indemnified party. In no event shall Seller's liability hereunder exceed the
amount of the Purchase Price that Seller has received in cash (including cash
amounts received under the 1999 Note).
ARTICLE 10
NON-COMPETITION
10.1 NON-COMPETE. Each of Seller and OXIS International agrees that it will
not, directly or indirectly (including, but not limited to, through any parent
company, subsidiary or affiliate), for a period of three (3) years from the
Closing Date, own, operate, engage in (which includes consulting and
manufacturing) or, except as provided below, have any interest, financial or
otherwise, in any person, firm, partnership, association, cooperative,
corporation, company, entity or business that engages or is involved in
(including researching, manufacturing, producing or selling) the therapeutic
drug monitoring assay business (except as necessary to fulfill obligations under
the Services Agreement). Notwithstanding the foregoing, Seller and/or OXIS
International may own, directly or indirectly, not more than a five percent (5%)
beneficial interest in the outstanding stock of any such entity. Seller shall
also not use for its own purposes the names related to the products being sold
as part of the Assets, including but not limited to "Innofluor". Buyer and
Seller agree that Seller is not selling to Buyer, and Buyer is not buying from
Seller, hereunder the name "OXIS" (or any derivation thereof); provided, however
that Buyer shall have a limited, non-exclusive, royalty-free license to use the
name "OXIS" in connection with the sale to customers of the products being sold
hereunder as part of the Assets for a period of 12 months following the Closing.
10.2 INJUNCTIVE RELIEF. Seller acknowledges it would be difficult to
compensate Buyer fully for damages for any violation of this Article 10.
Accordingly, Seller agrees that Buyer shall be entitled to temporary and
permanent injunctive relief to enforce the provisions of this Article in
addition to the right of Buyer to claim damages. Buyer acknowledges it would be
difficult to compensate Seller fully for damages for any violation of this
Article 10. Accordingly, Buyer agrees that Seller shall be entitled to temporary
and permanent injunctive relief to enforce the provisions of this Article in
addition to the right of Seller to claim damages.
ARTICLE 11
NONDISCLOSURE OF CONFIDENTIAL INFORMATION
11.1 NONDISCLOSURE AGREEMENT. Representatives of Seller and Buyer have
previously signed an agreement dated November 10, 1998, limiting the
distribution of confidential information. Except as otherwise provided in the
Services Agreement, all information not previously disclosed to the public or
generally known to persons engaged in the respective businesses of Buyer and
Seller which shall have been furnished by Buyer to Seller or by Seller to Buyer
as provided in this Agreement or otherwise in connection with the transactions
contemplated hereby, shall not be disclosed by the party receiving such
information to any person, other than its employees, legal counsel, financial
advisers, accountants or agents in confidence, or used for any purpose other
than as contemplated herein. In the event that the transactions contemplated by
this Agreement shall not be consummated, all such information which shall be in
writing shall promptly be returned to the party furnishing the same, including,
to the extent reasonably practicable, all copies or reproductions thereof which
may have been prepared.
ARTICLE 12
MISCELLANEOUS
12.1 AMENDMENT, WAIVERS AND CONSENTS. This Agreement and the schedules and
Exhibits hereto and that certain side letter between Buyer and Seller dated June
28, 1999 ("Side Letter") constitute the entire agreement between Seller and
Buyer as to the subject matter herein, and supersedes all prior negotiations,
proposals and representations (written or oral). To the extent any terms of this
Agreement or Exhibits hereto are inconsistent or conflict with the terms of the
Side Letter, the terms of the Side Letter shall govern. This Agreement shall not
be changed or modified, in whole or in part, except by supplemental agreement
signed by the parties. Any party may waive compliance by any other party with
any of the covenants or conditions of this Agreement, but no waiver shall be
binding unless executed in writing by the party granting the waiver. No waiver
of any provision of this Agreement shall be deemed, or shall constitute, a
waiver of any other provision, whether or not similar, nor shall any waiver
constitute a continuing waiver. Any consent under this Agreement shall be in
writing and shall be effective only to the extent specifically set forth in such
writing.
12.2 SUCCESSORS AND ASSIGNS. Neither Seller nor Buyer may assign this
Agreement except to their respective affiliates, or if they are acquired or
merged with another party the assignment of this Agreement to the new successor
entity shall be permitted. This Agreement shall bind and inure to the benefit of
the parties hereto and their respective successors and permitted assigns.
12.3 GOVERNING LAW. The rights and obligations of the parties shall be
governed by, and this Agreement shall be construed and enforced in accordance
with, the laws of the State of Oregon, excluding its conflict of laws rules to
the extent such rules would apply the law of another jurisdiction.
12.4 ATTORNEYS' FEES. If any party brings any suit, action, counterclaim,
or arbitration proceeding to enforce the provisions of this Agreement (including
without limitation enforcement of any award or judgment obtained with respect to
this Agreement), the prevailing party shall be entitled to recover a reasonable
allowance for attorneys' fees and litigation expenses in addition to court
costs.
12.5 DISPUTE RESOLUTION. Any dispute, controversy or claim between the
parties relating to, or arising out of or in connection with, this Agreement (or
any subsequent agreements or amendments thereto), including as to its existence,
enforceability, validity, interpretation, performance, breach or damages,
including claims in tort, whether arising before or after the termination of
this Agreement, shall be settled only by binding arbitration pursuant to the
Commercial Arbitration Rules, as then amended and in effect, of the American
Arbitration Association (the "Rules"), subject to the following:
12.5.1 There shall be one arbitrator, who shall be selected under the
normal procedures prescribed in the Rules.
12.5.2 Subject to legal privileges, each party shall be entitled to
discovery in accordance with the Federal Rules of Civil Procedure.
12.5.3 At the arbitration hearing, each party may make written and
oral presentations to the arbitrator, present testimony and written evidence and
examine witnesses.
12.5.4 The arbitrator's decision shall be in writing, shall be binding
and final and may be entered and enforced in any court of competent
jurisdiction.
12.5.5 No party shall be eligible to receive, and the arbitrator shall
not have the authority to award, exemplary or punitive damages.
12.5.6 Each party to the arbitration shall pay one-half of the fees and
expenses of the arbitrators and the American Arbitration Association.
12.5.7 The arbitrator shall not have the power to amend this
Agreement.
12.6 PAYMENT OF FEES AND EXPENSES. Except as otherwise set forth in this
Agreement, each of Seller and Buyer shall bear their own costs and expenses,
including without limitation, attorneys' fees, incurred in connection with the
negotiation and execution of this Agreement. Seller shall pay any applicable
sales and income taxes on Assets being sold.
12.7 RULES OF CONSTRUCTION. The parties acknowledge that each party has
read and negotiated the language used in this Agreement. The parties agree that,
because all parties participated in negotiating and drafting this Agreement, no
rule of construction shall apply to this Agreement which construes ambiguous
language in favor of or against any party by reason of that party's role in
drafting this Agreement.
12.8 ADDITIONAL DOCUMENTS. Each of the parties agree, without further
consideration, to execute and deliver such other documents and take such further
action as may be reasonably required to effectuate the provisions of this
Agreement.
12.9 SEVERABILITY. If any provision of this Agreement, as applied to either
party or to any circumstance, is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, this Agreement shall continue in full
force and effect without said provision.
12.10 EXHIBITS. All Exhibits and Schedules attached hereto shall be deemed
to be a part of this Agreement and are fully incorporated in this Agreement by
this reference.
12.11 NOTICES. All notices or other communications required or permitted
hereunder shall be made in writing and shall be deemed to have been duly given
and effective immediately if delivered by hand, or three (3) business days after
being mailed, postage prepaid, by first class or certified or registered mail,
return receipt requested, and addressed as follows:
To Buyer at: Opus Diagnostics, Inc.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇ ▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
Attn: President
To Seller at: OXIS Health Products, Inc.
▇▇▇▇ ▇. ▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: President
A notice of change of address shall be effective only when done in accordance
with this Section 12.11.
12.12 RIGHTS OF PARTIES. Nothing in this Agreement, whether express or
implied, is intended to confer any rights or remedies under or by reason of this
Agreement on any persons other than the parties to it and their respective
successors and assigns, nor is anything in this Agreement intended to relieve or
discharge the obligation or liability of any third person to any party to this
Agreement, nor shall any provision give any third person any right of
subrogation or action over or against any party to this Agreement.
12.13 COUNTERPARTS. This Agreement may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument.
IN WITNESS WHEREOF, the parties hereto have duly executed this Asset
Purchase Agreement as of the date first written above.
SELLER BUYER
OXIS HEALTH PRODUCTS, INC. OPUS DIAGNOSTICS, INC.
By: _________________________ By: _________________________
Title: ______________________ Title: ______________________
OXIS INTERNATIONAL, INC.*
By: _________________________
Title: ______________________
*Solely for purpose of making the agreement set forth in Article 10. No other
provision of the Agreement applies to OXIS International, Inc.
LIST OF SCHEDULES AND EXHIBITS
SCHEDULE NAME
1.1 Description of Seller's Therapeutic Drug Monitoring
Assay Business
4 Seller Disclosure Schedule
4.4 Inventory
4.5 Contracts
4.8 Seller Intellectual Property
4.10 Top Ten Customers
4.11 Compliance with Laws
EXHIBIT NAME
A Form of 1999 Note
B Form of Warrant
C Form of ▇▇▇▇ of Sale
D Form of Assignment of Intangible Property
E Form of Services Agreement
SCHEDULE 1.1
Description of Seller's
Therapeutic Drug Monitoring Assay Business
OXIS' Therapeutic Drug Monitoring Assay Business consists of manufacturing,
marketing and selling fourteen therapeutic drug monitoring ("TDM") assays,
related calibrator sets and control sets for two of the assays (collectively,
the "Products"). The Products, which are designed to run on ▇▇▇▇▇▇ Laboratories'
TDx and TDxFLx instruments, are used by customers to test patient samples for
the following therapeutic drugs:
- Amikacin
- Carbamazepine
- Digitoxin
- Digoxin
- Gentamicin
- Phenobarbital
- Phenytoin
- Quinidine
- Teicoplanin
- Theophylline
- Topiramate
- Tobramycin
- Valproic Acid
- Vancomycin
The Products are sold under the trademark "Innofluor".
SCHEDULE 4.5
Contracts
Contracts relating to OXIS' TDM Business:
Type of Contract Name Date
Development agreement Ortho Pharmaceutical Corporation** 04/1/94
Distribution: BioStat Diagnostics, Limited* 08/27/98
BDS Diagnostics 04/27/95
BioMedical Diagnostics Belgium* 12/28/98
BioMedical Diagnostics, France 09/01/91
▇▇▇▇▇▇▇, ▇▇▇▇▇▇** 01/04/94
Dispolab AG 11/01/92
Immuno Diagnostics 11/01/91
Infolab 09/01/91
Innogenetics Tecnologia, S.A. 04/01/96
Immucor Canada, Inc. 01/01/96
J&S Medical Associates 12/01/91
Labsco 01/01/92
Medial AG 10/14/97
New Zealand Diagnostics Limited 09/01/95
Quatro Biosystems Limited 09/01/93
▇▇▇▇ ▇▇▇▇▇▇▇ Biochemica GmbH 07/01/94
Schoeller Pharma 06/01/96
Sentinal Chemicals 09/01/95
Tema Ricerca S.R.L. 11/01/92
Federal Supply Schedule Dept. of Veterans' Affairs**
- latest amendment 01/13/99
*Contract includes distribution of OXIS' research products. This portion of the
contract is not included in the transaction. The contract will be terminated and
two new contracts will be entered into.
**Consent of other party is required to transfer the contract to Buyer. The
consents of ▇▇▇▇▇▇▇, Ortho and the Dept. of Veterans' Affairs will not be
obtained prior to Closing.
Significant Suppliers
AC Label Company
▇▇▇▇▇▇▇ Chemical
Alliance Plastics Finish Products ▇▇▇▇▇▇▇
Binding Site BioCell Laboratories ▇▇▇▇ Labels
Diagraph/▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Division Embassy Labels
▇▇▇▇▇▇ Scientific ▇▇▇▇▇▇▇▇▇▇ Industries Fluka
Chemical ▇▇▇▇▇▇▇ Brothers High Purity Chemical
Intergen Company Orbis Division ▇▇▇▇▇▇ Chemical
Poly-tainer Product Packaging Plus Scientific
Supply & Equipment Sigma Chemical Superprinters
Technapack Tharco Thinking Plastics Tursso
Company VWR Scientific West Company Wheaton
Scientific
SCHEDULE 4.8
Seller's Intellectual Property
Trademark - OXIS' TDM assays are sold using the registered trademark "INNOFLUOR"
(U.S. registration no. 2,005,698).
Patent - A patent protecting OXIS' Topiramate assay has been allowed, but not
yet issued (U.S. application no. 08/565,143).
SCHEDULE 4.10
Seller's Top 10 Customers
Year ended December 31, 1998:
Customer Name 1998 Sales
Bio-Stat Limited $308,571
BioMedical Diagnostics, France $260,631
▇▇▇▇ ▇▇▇▇▇▇▇ Biochemica GMBH $129,670
Immuno-Biological Laboratories Co., Ltd. $91,630
BioMedical Diagnostics, Belgium $41,938
Medical Sales Associates $37,910
Tema Ricerca SRL $36,709
SmithKline ▇▇▇▇▇▇▇ $33,160
Ral Tecnia Para el Laboratorio $32,533
Sanova Diagnostik $32,072
Three months ended March 31, 1999:
Q1 1999
Customer Name Sales
BioMedical Diagnostics, France $76,833
Bio-Stat Limited $52,499
Alexon Trend (Seradyn) $50,710
BioMedical Diagnostics, Belgium $49,769
▇▇▇▇ ▇▇▇▇▇▇▇ Biochemica GMBH $45,905
Immuno-Biological Laboratories Co., Ltd. $34,260
SmithKline ▇▇▇▇▇▇▇ $15,705
Ral Tecnia Para el Laboratorio $12,506
Medical Sales Associates $12,050
Tema Ricerca SRL $10,222
SCHEDULE 4.11
Compliance with Laws
510(k) Clearance Letters
Gentamicin Reagent August 1, 1997
Phenobarbital Reagent July 14, 1998
Phenytoin Reagent January 24, 1996
Theophylline Reagent March 15, 1985
Tobramycin Reagent August 17, 1987
Vancomycin Reagent August 17, 1987
Digoxin Reagent October 30, 1989
Amikacin Reagent February 9, 1996
Quinidine Reagent April 4, 1996
Carbamazepine Reagent August 10, 1989
Valproic Acid Reagent July 15, 1991
Digitoxin Reagent September 23, 1991
Topiramate Reagent May 12, 1997
Gentamicin Calibrator July 21, 1987
Phenobarbital Calibrator July 21, 1987
Phenytoin Calibrator July 21, 1987
Theophylline Calibrator July 21, 1987
Tobramycin Calibrator July 21, 1987
Vancomycin Calibrator July 21, 1987
Digoxin Calibrator October 30, 1989
Amikacin Calibrator August 22, 1990
Quinidine Calibrator June 9, 1989
Carbamazepine Calibrator August 15, 1989
Valproic Acid Calibrator May 23, 1991
Digitoxin Calibrator August 30, 1991
Topiramate Calibrator May 12, 1997
Topiramate Control May 12, 1997
